摘要
目的评估乳腺癌患者新辅助或辅助化疗期间应用3月或1月剂型亮丙瑞林对卵巢功能的保护作用。方法纳入接受新辅助或辅助化疗的小于45岁HR阴性乳腺癌患者,用3月剂型亮丙瑞林(3M-GnRHa)或1月剂型亮丙瑞林(1M-GnRHa)进行卵巢保护的患者各50例。对患者的基线特征、病例资料、肿瘤特征、化疗期间的抗缪勒激素水平(AMH)及月经状态进行分析,在第1周期化疗开始前1周内、化疗中期、化疗后6月和化疗后12月连续监测2组血清AMH水平及月经状态。结果 3M-GnRHa组与1M-GnRHa组患者在化疗结束后6月的AMH低水平率分别为14%(7例/50例)和12%(6例/50例),化疗结束后12月AMH低水平率分别为12%(6例/50例)和10%(5例/50例),差异无统计学意义(P> 0.05)。除了"41~45岁"年龄段,其他年龄段患者AMH基本能恢复至化疗前水平,并且大部分患者月经状态于化疗结束后12月恢复。亚组分析发现,无论化疗方案分组还是年龄分组,2组的AMH水平和月经状态恢复水平均一致,差异无统计学意义。结论 3M-GnRHa与1M-GnRHa在年轻乳腺癌化疗期间均具有一定的卵巢保护功能。
Objective To evaluate the protective effect of three or one month dosage form of leproteroline on ovarian function in breast cancer patients during neoadjuvant or adjuvant chemotherapy.Methods HRnegative breast cancer patients younger than 45 years of age who received neoadjuvant or adjuvant chemotherapy were included in the study.Fifty patients were treated with 3-month leproteroline(3 M-GnRHa) and 50 patients were treated with 1-month leproteroline(1 M-GnRHa) for ovarian protection.Patients’ baseline characteristics,case data,tumor characteristics,anti-mulerian hormone(AMH) level and menstrual status during chemotherapy were analyzed.Serum AMH level and menstrual status were continuously monitored in two groups at 1 week before the start of the first cycle of chemotherapy,in the middle of chemotherapy,6 months and 12 months after chemotherapy.Results The low rates of AMH in 3 M-GnRHa group and 1 M-GnRHa group at6 months after chemotherapy were 14%(7 cases/50 cases) and 12%(6 cases/50 cases),the low rates of AMH 12 months after chemotherapy were 12%(6 cases/50 cases) and 10%(5 cases/50 cases),the difference was not statistically significant(P> 0.05),Except for the "41-45" age group,the AMH of patients in other age groups could basically return to the prechemotherapy level,and the menstrual status of most patients recovered at 12 months after the end of chemotherapy.Subgroup analysis showed that AMH level and menstrual state recovery level were consistent between the two groups regardless of chemotherapy regimens or age groups,with no statistically significant difference.Conclusion Both 3 M-GnRHa and 1 M-GnRHa have certain ovarian protection during chemotherapy for young breast cancer.
作者
陈木兰
林海燕
吴凡
王丽莉
黄伟炜
李娜妮
黄静
CHEN Mu-lan;LIN Hai-yan;WU Fan;WANG Li-li;HUANG Wei-wei;LI Na-ni;HUANG Jing(Department of Breast CancerCancer Hospital,Fujian Cancer Hospital,Fuzhou 350011,Fujian Province,China;Department of Pharmacy,Fujian Medical University,Cancer Hospital,Fujian Cancer Hospital,Fuzhou 350011,Fujian Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2021年第19期2581-2583,共3页
The Chinese Journal of Clinical Pharmacology
基金
福建医科大学起航基金资助项目(2018QH1226)。
关键词
乳腺癌
卵巢保护
促性腺激素释放激素激动药
breast cancer
ovarian function protection
gonadotropin-releasing hormone agonists
